Lecturers
ISOBM2020 Lecturers
(tentative list at the moment)
Lecturers
| Lecturer | Title of Lecture |
|---|---|
| Barak Vivian (ISR) | – sIL-2R- an important Immuno- Biomarker for Cancer |
| Bendas G (GER) | to be announced |
| Blatnik Ana (SLO) | Genetic modifiers of risk in hereditary cancer – an analysis of Slovenian NBN 657del5 carriers |
| Boltežar Gašper (SLO) | Tumour markers of mucinoses cists of pancreas |
| Bombač Alenka (SLO) | Mutational spectrum in patients with metastatic gastrointestinal stromal tumours treated at Institute of Oncology Ljubljana |
| Bronkhorst A (ZAR) | Understanding biology of cell-free nucleic acids for clinical decision making |
| Chechlinska Magdalena (POL) | Molecular profiling of ovarian tumour microenvironment |
| Colas Ortega Eva (ESP) | Use of biomarkers in diagnosis and presurgical patient stratification |
| Danesi Romano (ITA) | Clinical implementation of pharmacogenetics to reduce the risk of toxicity of anticancer drugs |
| Datar Vineet (IND) | New Dynamics in Cancer Outcomes: Encyclopaedic Tumour Analysis |
| Del Re Marizia (ITA) | The application of liquid biopsy to cancer treatment monitoring |
| Devjak Rok (SLO) | Oncogenic driver EGFR mutation in NSCLC with case report |
| Diamandis P. Eleftherios (CAN) | Circulating tumour DNA for early cancer detection |
| Duffy Joe (IRL) | Personalised treatment for cancer: biomarkers are showing the way |
| Einarsson Roland (SWE) | Bladder Cancer detection by UBC rapid |
| Fanfani Francesco (ITA) | Personalised surgical approach in early endometrial cancer according to bimolecular profile |
| Ferrari Paola (ITA) | Inhibiting immunosuppression immunotherapy in solid tumors |
| Fishmann Dmytro (EST) | Machine learning in medicine |
| Fritche, Herb (USA) | Ovarian cancer markers |
| Garrido Manuel (PRT) | Multi-biomarker panels for risk stratification in prostate cancer patients with PSA between 2 and 10 ng/ml |
| Habermann Jens (GER) | to be announced |
| Haselmann Verena (GER) | Liquid biopsy for immune therapies |
| van den Heuvel Michael (NED) | Biomarker guided treatment of patients with advanced lung cancer |
| Holdenrieder Stefan (GER) | Proteomic and metabolomics multimarker approaches for lung cancer |
| Illig Thomas (GER) | The relevance of high-quality bio banking in research |
| Janša Rado (SLO) | Clinical importance of alpha-fetoprotein in hepatocellular carcinoma |
| Kagan Jacob (USA) | Validation Studies of Biomarkers for Early Detection of Aggressive Prostate Cancer |
| Karlikova Marie (CZE) | Importance of Matrix metalloproteinases in tumour diseases |
| Kinkorova Judita (CZE) | Biobanks in Corona Pandemy |
| Klawonn Frank (GER) | Biostatistic approaches for evaluation of complex longitudinal ring trial data |
| Kloft Charlotte (GER) | to be announced |
| Krüger Kimberly (GER) | Proteomic and metabolomic multimarker approaches for lung cancer |
| Kučera Radek (CZE) | The importance of PHI for the prediction of surgical solution or active surveillance of prostate cancer patients |
| Lainšček Duško (SLO) | An enhanced CRISPR based tool for treating chronic myelogenous leukaemia |
| Leendert Looijenga (NED) | Human germ cell tumours; clinical implementation of laboratory findings |
| Marc Janja (SLO) | Biomarkers in bone metastasis |
| Mlinarič-Raščan Irena (SLO) | Prostaglandin E Receptor 4 Agonist as Promising Therapeutic Agent for Treatment of Chronic Lymphocytic Leukaemia |
| Muley Thomas (GER) | Use of tumor marker classificators for post-surgery stratification of patients with early lung cancer |
| Nazarenko Irina (GER) | to be announced |
| Nicolini Andrea (ITA) | A new immunotherapy schedule in metastatic endocrino-dependent breast cancer patients |
| Norčič Gregor (SLO) | Potential clinical use of liquid biopsy in abdominal surgery |
| Ohta Nobuhio (ROC) | Autofluorescence lifetime microscopy and nanosecond pulsed electric field effects in live cells: A comparison between cancerous cells and non-malignant normal cells |
| Oehr Peter (JPN) | New established types of ROC-curves and their innovative clinical impact |
| Osredkar Joško (SLO) | National screening programmes; how and when? |
| Pečen Ladislav (CZE) | Decision support systems for the interpretation of tumor markers |
| Pfaffl Michael (GER) | to be announced |
| Rebmann V (GER) | to be announced |
| Reijnen Casper (NED) | Integrating biomarkers into ENDORISK prediction model |
| Ritter Christoph (GER) | to be announced |
| Romano Andrea (NED) | Hormonal treatment in gynaecologic malignancy. Is there a place? |
| van Rossum Huub (NED) | Algorithms for classification of response to therapy in lung cancer patients |
| Roychowdhury Ansuya (IND) | HIF1alpha-dependent upregulation of ATAD2 promotes proliferation and migration of stomach cancer cells in response to hypoxia |
| Schippan Inga (GER) | Risk prediction for GvHD in patients with AML after stem cell transplantation |
| Schroeder Christoph (GER) | Affinity proteomics for the discovery of novel biomarkers and therapeutic targets |
| Sever Matjaž (SLO) | Clinical implication of CART therapy |
| Smrkolj Tomaž (SLO) | Biomarkers in urology |
| Song Erwei (CHN) | Combating the microenvironment of breast cancer |
| Stegel Vida (SLO) | Genetic testing of ovarian tumour samples at the Institute of oncology Ljubljana |
| Strojnik Ksenija (SLO) | Germline genetic testing for cancer treatment in prostate and pancreatic cancer patients |
| Škerl Petra (SLO) | Methylation status of mismatch repair genes in endometrial and colorectal cancer |
| Škof Erik (SLO) | Clinical importance of BRCA mutation in ovarian cancer |
| Šmid Lojze (SLO) | Chromogranin in the diagnostic and therapy of neuroendocrine tumours |
| Šterajčič Dragoš Vita (SLO) | The use of RNAseq in discovery of splicing abnormalities |
| Thakur B (GER) | to be announced |
| Tokarz Janina (GER) | Metabolomics for deep phenotyping in frequent human diseases |
| Topolčan Ondrej (CZE) | Significance tumour biomarkers for tumour aggressiveness |
| Turnšek Nina (SLO) | Oncogenic driver ALK fusion in NSCLC with case report |
| Uhlig Carsten (GER) | Artificial intelligence approaches for tumor marker evaluations |
| Ungerer V (GER) | Epigenetic changes of circulating nucleosomes as new cancer biomarkers |
| Unk Mojca (SLO) | (R)Evolution of non-small cell lung cancer systemic treatment |
| Viehbaum Laura (GER) | Longitudinal inter-lab and inter-manufacturer comparison of gastrointestinal and gynecological tumor markers |
| Windrichova Jindra (CZE) | Digital PCR assessment of KRAS mutations in plasma cell-free DNA in liver metastatic colorectal cancer |
| Wojtajewicz Natalie (POL) | Longitudinal inter-lab and inter-manufacturer comparison of lung and urological tumor markers |
| Zagorac Andreja (SLO) | Evaluation of Xpert®Bladder Cancer Detection and UroVysion Bladder Cancer Kit in detection of bladder cancer |
ENITEC Section
| Lecturer | Title of Lecture |
|---|---|
| Alicia Leon del Castillo (NLD) | TCGA classification in endometrial cancer and beyond |
| Casper Reijnen (NLD) | Integrating biomarkers into ENDORISK prediction model |
| Francesco Fanfani (ITA) | Personalised surgical approach in early endometrial cancer according to bimolecular profile |
| Eva Colas Ortega (ESP) | Use of biomarkers in diagnosis and presurgical patient stratification |
BioEndoCar Section
| Lecturer | Title of Lecture |
|---|---|
| Thomas Illig (GER) | The relevance of high-quality biobanking in research |
| Janina Tokarz (GER) | Metabolomics for deep phenotyping in frequent human diseases |
| Christoph Schroeder (GER) | Affinity proteomics for the discovery of novel biomarkers and therapeutic targets |
| Dmytro Fishman (EST) | Machine learning in medicine |